The clinical improvements seen with these new treatments have led clinicians to rely on functional status, age at treatment initiation, number of SMN2 copies and age at symptom onset, rather than the classical SMA subtypes, to define clinical SMA phenotypes [22,23]. Here, SMN2 is linked to proximal spinal muscular atrophy.